The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion and analysis.
A biotechnology firm is releasing data on three failed efforts to confirm findings in high-profile scientific journals — details that the industry usually keeps secret.
Amgen, headquartered in Thousand Oaks, California, says that it hopes the move will encourage others in industry and academia to describe their own replication attempts, and thus help the scientific community to get to the bottom of work that other labs are having trouble verifying.
The data are posted online at a newly launched channel dedicated to quickly publishing efforts to confirm scientific findings. The ‘Preclinical Reproducibility and Robustness’ channel is hosted by F1000Research, the publishing platform of London-based publishers Faculty of 1000 (F1000). Scientists who are concerned about the irreproducibility of preclinical research say that they welcome the initiative — but are not sure whether it will gain traction.
The idea emerged from discussions at a meeting focused on improving scientific integrity, hosted by the US National Academy of Sciences in 2015. Sasha Kamb, who leads research discovery at Amgen, said that his company’s scientists have in many instances tried and failed to reproduce academic studies, but that it takes too much time and effort to publish these accounts through conventional peer-review procedures.
Read full, original post: Biotech giant publishes failures to confirm high-profile science
